Skip to main content
OpenTrials
Completed

NCT Number: NCT01059695

Analysis of the Results of Treatment for Cervical Carcinoma in Limburg

Analysis of all women treated for cervical cancer between 2000 and 2008 in Limburg, a province in the south of the Netherlands. Patient characteristics, diagnosis, treatment modalities, complications and survival will be analyzed by record review. Quality of life of the living study population will be assessed using the EORTC QLQ-C30 and QOQ-CX24 questionnaire. Patients will be identified via registration data from the Integraal Kankercentrum Limburg.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • cervical cancer FIGO stage IB-1 to IVB
  • Treated in Limburg between 2000 and 2008

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. Quality of life

    Quality of life of the living study population will be assessed using the EORTC QLQ-C30 and QOQ-CX24 questionnaire

Sponsors and collaborators

Lead sponsor

Maastricht Radiation Oncology

Other

Collaborators

  • Atrium Medical Center
  • Maastricht University Medical Center

Registry information

Official study title

Retrospective Analysis of Treatment and Quality of Life of Women Treated for Cervical Carcinoma FIGO Stage IB-1 to IVb From 2000-2008 in Limburg, a Province in the South of the Netherlands.

Acronym: CervixLimburg

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Feb 1, 2010
Registry last updated
Jan 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.